Bladder Cancer Clinical Trials & Research

CLINICAL TRIAL 17970

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Disease Site: Lung

CLINICAL TRIAL 18680

A study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

Disease Site: Urinary Bladder, Bladder

CLINICAL TRIAL 18964

Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 19480

The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Bempegaldesleukin (Nktr-214) And In combination With Bempegaldesleukin (Nktr-214) Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies

Disease Site: Any Site, Bones and Joints, Breast, Colon, Corpus Uteri, Eye and Orbit, Lung, Melanoma, Skin - Do Not Use, Ovary, Soft Tissue, Urinary Bladder

CLINICAL TRIAL 19627

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Disease Site: Non-Hodgkin's Lymphoma, Lymphoma

CLINICAL TRIAL 19715

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 19829

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Disease Site: Non-Hodgkin's Lymphoma, Lymphoid Leukemia

CLINICAL TRIAL 19873

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)

Disease Site: Urinary Bladder

CLINICAL TRIAL 19877

A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 19960

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic Car T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 19981

A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma

Disease Site: Urinary Bladder, Urothelial Cancer

CLINICAL TRIAL 19988

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Disease Site: Urinary Bladder, Urothelial Cancer

CLINICAL TRIAL 20050

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Disease Site: Urinary Bladder

CLINICAL TRIAL 20069

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

CLINICAL TRIAL 20078

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Disease Site: Lung, Non-Hodgkin's Lymphoma

CLINICAL TRIAL 20131

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other hematologic

CLINICAL TRIAL 20266

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Disease Site: Hodgkin's Lymphoma, Other hematologic, Unknown Primary Site

CLINICAL TRIAL 20297

Cabozantinib plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

Disease Site: Urinary Bladder, Urothelial Cancer

CLINICAL TRIAL 20361

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies and In Combination With Daratumumab As A Salvage Regimen for Multiple Myeloma

Disease Site: Multiple Myeloma

CLINICAL TRIAL 20373

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Disease Site: Lung, Non small cell lung cancer

CLINICAL TRIAL 20385

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin(Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma

CLINICAL TRIAL 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 20575

A Phase 1 Study of CG0070 Combined with Nivolumab in Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)

Disease Site: Urinary Bladder

CLINICAL TRIAL 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Non-Hodgkin's Lymphoma, Lymphoma

CLINICAL TRIAL 20600

A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies

Disease Site: Lymphoma, Unknown Sites

CLINICAL TRIAL 20608

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma

CLINICAL TRIAL 20712

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV- Associated Solid Tumors, with Expansion Cohorts in HIV-Associated Solid tumors and a Cohort of HIV- Associated Classical Hodgkin Lymphoma

CLINICAL TRIAL 20814

Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group

Disease Site: Leukemia, other

CLINICAL TRIAL 90001

A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

Disease Site: Hodgkin's Lymphoma

CLINICAL TRIAL 20126

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)

Disease Site: Non-Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Leukemia, other, Hodgkin's Lymphoma, Lymphoid Leukemia, Acute Leukemia (ALL, AML), Myelodysplastic syndrome (MDS), NHL - Anaplastic large cell lymphoma (ALCL), NHL - Burkitt's lymphoma, NHL - Diffuse large cell lymphoma, NHL - lymphoblastic lymphoma, Other leukemia

CLINICAL TRIAL 20372

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 20397

A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Disease Site: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

CLINICAL TRIAL 50376

Pilot Study of Using MRD as a Predictor of Response after Axicabtagene Ciloleucel in Patients with Indolent Lymphomas

Disease Site: Non-Hodgkin's Lymphoma

CLINICAL TRIAL 18783

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Leukemia, other, Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Acute Leukemia (ALL, AML), Chronic Leukemia (CLL, CML), Other leukemia

CLINICAL TRIAL 19724

Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release

Disease Site: Leukemia, other, Acute Leukemia (ALL, AML), Other leukemia

CLINICAL TRIAL 19733

Motivating a Spectrum of Cancer Patients to Quit Smoking: Intervention Development and Feasibility

Disease Site: Rectum, Other Female Genital, Urinary Bladder, Breast, Colon, Melanoma, skin, Bladder, Breast Cancer, Colorectal, Melanoma, Ovarian, Uterus, Vaginal, Vulva